U.S. Residential REITs Stock News

NasdaqGS:INCY
NasdaqGS:INCYBiotechs

What Incyte (INCY)'s Expanded Opzelura EU Approval Means For Shareholders

In the past week, Incyte reported that the European Commission approved Opzelura (ruxolitinib) cream for moderate atopic dermatitis in adults who do not respond adequately to or cannot use standard topical therapies, expanding the drug’s European label beyond non-segmental vitiligo. This decision, backed by strong Phase 3 data showing rapid itch relief and durable skin clearance with a favorable safety profile, coincided with Incyte posting higher quarterly revenue and net income and raising...
NasdaqGS:EVCM
NasdaqGS:EVCMSoftware

Why EverCommerce (EVCM) Is Down 8.8% After Softened 2026 Outlook And CEO Transition - And What's Next

EverCommerce Inc. has reported past second-quarter 2026 results showing revenue of US$152.02 million and net income of US$9.72 million, while also tightening its full-year 2026 revenue outlook toward the lower end of its US$612 million to US$632 million guidance range. On top of these earnings and guidance updates, the board’s decision to appoint experienced technology operator Alex Goor as CEO and director, with founder Eric Remer stepping back from executive leadership but remaining on the...
NasdaqGS:CHEF
NasdaqGS:CHEFConsumer Retailing

Did Chefs' Warehouse's (CHEF) Strong Q2 and New Term Loan Just Redefine Its Investment Narrative?

In late July 2026, The Chefs' Warehouse, Inc. reported higher second-quarter sales of US$1,168.61 million and net income of US$33.77 million year over year, then in early August began marketing a new US$625 million term loan facility to refinance existing debt and convertible notes, cover related costs, and support general corporate purposes. Taken together, stronger recent profitability, raised full-year 2026 sales guidance of US$4.50 billion to US$4.60 billion, and a potential balance...
NYSE:MMS
NYSE:MMSProfessional Services

Did Lowered 2026 Guidance After VA Incentive Pause Just Shift Maximus' (MMS) Investment Narrative?

In August 2026, Maximus, Inc. reported third-quarter results showing revenue of US$1,278.97 million and net income of US$103.59 million, while also updating its fiscal 2026 guidance to revenue of US$5.20–US$5.35 billion, net income of US$376–US$392 million, and diluted EPS of US$6.94–US$7.24, with outcomes expected toward the lower end of ranges. The company’s revised outlook followed a Department of Veterans Affairs decision to pause performance incentives on its Medical Disability Exam...
NYSE:SITE
NYSE:SITETrade Distributors

SiteOne’s Buybacks And Acquisition Push Could Be A Game Changer For SiteOne Landscape Supply (SITE)

In late July 2026, SiteOne Landscape Supply reported second-quarter sales of US$1,530.7 million and net income of US$139.3 million, alongside confirmation that it had repurchased 897,778 shares for US$103.76 million under its ongoing buyback program. Management also highlighted an active acquisition pipeline, with two deals already completed in 2026 adding about US$110 million in trailing sales, signalling continued emphasis on growth through consolidation in a fragmented landscape supply...
NYSE:LMT
NYSE:LMTAerospace & Defense

Lockheed Martin (LMT) Lands Major Defense Wins, Is The Upside Already Priced In?

What triggered fresh interest in Lockheed Martin stock Lockheed Martin (LMT) is back in focus after historic Q2 2026 results, large long term missile contracts, and a successful AI driven fighter jet test that together sharpen visibility on its defense business. See our latest analysis for Lockheed Martin. Against this backdrop of contracts and technology milestones, Lockheed Martin’s share price has moved up to $587.95, with an 18.28% year to date share price return and a 41.65% total...
NYSE:CBT
NYSE:CBTChemicals

Can Cabot (CBT) Justify Its Valuation Following Weaker Earnings And A CEO Transition?

Cabot (CBT) has drawn investor attention after third quarter earnings on 3 August 2026 showed sharply lower net income and earnings per share, along with previously announced leadership changes at the top of the company. See our latest analysis for Cabot. Cabot's recent earnings miss and upcoming CEO transition sit against a share price that has climbed 30.68% year to date, with a 5 year total shareholder return of 77.28%. This suggests longer term momentum has been stronger than the shorter...
NYSE:VTR
NYSE:VTRHealth Care REITs

Raised 2026 Earnings Outlook On Senior Housing Strength Might Change The Case For Investing In Ventas (VTR)

In late July 2026, Ventas, Inc. reported Q2 results showing revenue of US$1.73 billion and net income of US$70.57 million, while slightly lower basic and diluted EPS from continuing operations came in at US$0.14. At the same time, Ventas modestly raised its full-year 2026 attributable net income per share guidance range and midpoint, signaling increased confidence tied to strong senior housing operating performance and higher planned investment in that segment. Next, we’ll examine how this...
NYSE:CPRI
NYSE:CPRILuxury

Capri Holdings (CPRI) Is Down 6.5% After Raising EPS Guidance Despite Kors Inventory Delays

Capri Holdings Limited recently reported past first-quarter 2027 results, with sales easing to US$769 million while net income rose to US$69 million, and issued new second-quarter and full-year guidance outlining revenue pressures from Michael Kors inventory delays, softer EMEA demand and foreign exchange headwinds. Alongside this, Capri filed a US$41.30 million shelf registration for 2,500,000 common shares tied to an employee share offering, adding a capital structure element to investors’...
BATS:CBOE
BATS:CBOECapital Markets

How Record Q2 Results and Expanded Bond SFT Clearing Will Impact Cboe Global Markets (CBOE) Investors

Cboe Global Markets recently reported record second-quarter 2026 results, with revenue rising to US$1.44 billion and net income to US$353.1 million, while also expanding Cboe Clear Europe’s Securities Financing Transactions clearing service to include fixed income lending across major EU, UK, Swiss and U.S. bond markets. This combination of stronger earnings and the move to centrally clear bond lending underscores Cboe’s push to deepen its role in global market infrastructure. We’ll now...
NasdaqCM:BLFS
NasdaqCM:BLFSLife Sciences

Why BioLife Solutions (BLFS) Is Up 7.8% After Swinging To Q2 Profitability And What's Next

In the second quarter of 2026, BioLife Solutions, Inc. reported sales of US$28.47 million, up from US$23.44 million a year earlier, and moved from a net loss of US$15.84 million to net income of US$45.1 million, with basic earnings per share from continuing operations rising from a loss of US$0.32 to earnings of US$0.92. For the first half of 2026, the company’s sales increased to US$55.97 million from US$45.49 million, while net income shifted from a loss of US$16.29 million to a profit of...
NasdaqGS:GH
NasdaqGS:GHHealthcare

Guardant Health (GH) Is Up 6.1% After Raising 2026 Revenue Outlook And Filing Shelf Registration - Has The Bull Case Changed?

In late July 2026, Guardant Health reported second-quarter 2026 results showing sales of US$334.98 million and a net loss of US$120.14 million, alongside higher full-year revenue guidance of US$1.34–1.36 billion. The company also filed an omnibus shelf registration covering multiple securities and highlighted surging Shield screening volumes supported by new UnitedHealth coverage and recent FDA approvals. Next, we’ll examine how Guardant Health’s increased 2026 revenue guidance, underpinned...
NYSE:CPT
NYSE:CPTResidential REITs

Camden’s California Exit and Capital Shifts Might Change The Case For Investing In Camden Property Trust (CPT)

In recent weeks, Camden Property Trust completed the US$1.63 billion sale of its California portfolio, filed an US$802.87 million shelf registration for 7,250,000 common shares tied to an ESOP, updated 2026 earnings guidance, and finished a US$302.20 million share repurchase program covering 4,062,166 shares. These moves mark a significant repositioning of the portfolio toward newer Sunbelt assets while simultaneously shifting capital between buybacks and employee ownership, all against a...
NYSE:OC
NYSE:OCBuilding

What Is Behind Owens Corning (OC) Shares Climbing Today?

How Owens Corning’s Latest Earnings Shape the Story for Investors Owens Corning (OC) has attracted fresh attention after its second quarter 2026 earnings update, which paired broadly steady sales with softer profits, ongoing buybacks, and clearer guidance on upcoming segment trends and costs. See our latest analysis for Owens Corning. The earnings release and the appointment of a new CFO have come alongside brisk share price momentum for Owens Corning, with a 31.1% 90-day share price return...
NasdaqGS:GERN
NasdaqGS:GERNBiotechs

Geron (GERN) Is Up 15.6% After Raising 2026 RYTELO Revenue Guidance And Filing New ESOP Shares

In August 2026, Geron Corporation reported second-quarter 2026 results showing revenue of US$57.48 million versus US$49.04 million a year earlier, alongside a six-month net loss of US$20.32 million, and issued 2026 guidance projecting RYTELO net product revenue between US$220 million and US$240 million. The company also filed a US$6.03 million shelf registration for 4,500,000 common shares tied to an ESOP, highlighting ongoing use of equity-based compensation. We’ll now examine how Geron’s...
NasdaqGS:PCRX
NasdaqGS:PCRXPharmaceuticals

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data

Pacira BioSciences recently reported that its investigational gene therapy PCRX-201 for knee osteoarthritis showed positive two-year Phase 1 results, with a single intra-articular dose appearing well tolerated and associated with improvements in pain, stiffness, and function, and incorporated glucocorticoid pretreatment into its ongoing Phase 2 ASCEND study following favorable safety findings. By pairing encouraging long-term clinical data with a successful transition to scalable U.S.-based...
NYSE:NBHC
NYSE:NBHCBanks

National Bank Holdings (NBHC) Affirms Dividend, Is The Valuation Discount Enough?

Dividend affirmation puts National Bank Holdings in focus National Bank Holdings (NBHC) has drawn fresh attention after its board declared a quarterly cash dividend of $0.32 per share, payable on September 15, 2026 to shareholders of record on August 28. See our latest analysis for National Bank Holdings. Alongside the confirmed dividend, National Bank Holdings shares trade at $42.62, with the 1 month share price return down 3.86% while the year to date share price return is up 12.45% and the...